This article was displayed on the ChosunBiz MoneyMove (MM) site at 5:36 p.m. on Jun. 1, 2026.
Lotte Corporation's credit support burden related to Lotte Biologics is growing. As of the end of the first quarter this year, the outstanding debt subject to the funding replenishment agreement that Lotte Corporation provided for Lotte Biologics' facility loan stood at 830 billion won, approaching the total commitment limit of 900 billion won.
This does not mean cash will immediately leave Lotte Corporation. But analysts said that if Lotte Biologics' new-business investments gather pace, additional participation in paid-in capital increases or funding top-ups may be needed. That could also affect Lotte Corporation's shareholder return policies, including dividends and share cancellations.
According to the investment banking (IB) industry on the 1st, Lotte Corporation has a funding replenishment agreement with Hana Bank related to subsidiary Lotte Biologics' facility loan. The outstanding debt subject to the agreement rose from 550 billion won at the end of last year to 830 billion won at the end of the first quarter this year. That is 92.2% of the total commitment of 900 billion won. The maturity is at the end of Nov. 2031.
The loan also carries Lotte Construction's completion guarantee. Lotte Construction has committed to complete the contract manufacturing facility for pharmaceuticals by Dec. this year. The structure bolsters repayment stability for the borrowing fund through Lotte Corporation, while Lotte Construction bears the plant completion risk.
A funding replenishment agreement is a type of credit enhancement in which a parent company, etc., promises to make up any shortfall if the borrower fails to secure sufficient funds to repay principal and interest. If Lotte Biologics fails to repay principal and interest on time, the holding company must fill the shortfall, representing a potential burden.
The increase in outstanding debt subject to replenishment is interpreted as an expansion in the execution of Lotte Biologics' facility borrowings. As large-scale facility investments such as the Songdo Bio Campus ramp up, related borrowings appear to have increased.
Lotte Corporation's support for Lotte Biologics is not limited to the funding replenishment agreement. In Apr.–May last year, Lotte Corporation injected a total of 168 billion won into Lotte Biologics' paid-in capital increase. In Mar. this year, the agenda item for Lotte Corporation to participate in Lotte Biologics' paid-in capital increase also passed Lotte Corporation's Transparency Management Committee. Lotte Corporation is also providing debt guarantees totaling $110 million for Lotte Biologics' U.S. subsidiary.
Industry officials noted that increased bio investment could affect Lotte Corporation's shareholder return policy. Through its 2024–2026 three-year shareholder return policy, Lotte Corporation said it would raise the shareholder return ratio to 35% or more. Last year it also raised the common share dividend from 1,200 won to 1,250 won per share.
The bio business is still in a phase where large-scale investments come first. If Lotte Biologics needs additional funds during the completion and initial operation of the Songdo Bio Campus, additional participation by Lotte Corporation in capital increases, an expansion of the funding replenishment agreement, or further credit enhancement could be revisited. In that case, it could affect the holding company's cash flow and its capacity for shareholder returns such as dividends and share cancellations.
Shareholder interest is also growing. At Lotte Corporation's regular shareholders meeting this year, 20 shareholders spoke, up sharply from eight the year before. Key remarks included questions about dividends, the share price, and treasury shares, as well as the progress of new businesses. As the bio business is presented as a future growth pillar for Lotte Group, shareholder interest appears to have risen regarding the scale of investment and the timing of returns.
Lotte Biologics has set a goal of turning to profit next year, when Incheon Songdo Plant 1 goes into full operation. If things go as planned, financial concerns could ease somewhat, but if the timeline extends, analysts said the burden could fall on the parent company.